A practical reference on Copper(II): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Geological Survey, and Kathleen Crane of Scripps Institution of Oceanography. This team published their observations of the vents, organisms, and the composition of the vent fluids in the journal Science. In 1979, a team of biologists led by J. Frederick Grassle, at the time at WHOI, returned to the same location to investigate the biological communities discovered two year earlier. High temperature hydrothermal vents, the "black smokers", were discovered in spring 1979 by a team from the Scripps Institution of Oceanography using the submersible Alvin. The RISE expedition explored the East Pacific Rise at 21° N with the goals of testing geophysical mapping of the sea floor with the Alvin and finding another hydrothermal field beyond the Galápagos Rift vents. The expedition was led by Fred Spiess and Ken Macdonald and included participants from the U.S., Mexico and France. The dive region was selected based on the discovery of sea floor mounds of sulfide minerals by the French CYAMEX expedition in 1978. Prior to dive operations, expedition member Robert Ballard located near-bottom water temperature anomalies using a deeply towed instrument package. The first dive was targeted at one of those anomalies. On Easter Sunday April 15, 1979 during a dive of Alvin to 2,600 meters, Roger Larson and Bruce Luyendyk found a hydrothermal vent field with a biological community similar to the Galápagos vents. On a subsequent dive on April 21, William Normark and Thierry Juteau discovered the high temperature vents emitting black mineral particle jets from chimneys; the black smokers.
==== Southeast Raleigh ==== Southeast Raleigh is bounded by downtown on the west, Garner on the southwest, and rural Wake County to the southeast. The area includes areas along Rock Quarry Road, Poole Road, and New Bern Avenue. Primary neighborhoods include Abbington Ridge, Pearl Ridge, Chastain, Chavis Heights, Raleigh Country Club, Southgate, Kingwood Forest, Rochester Heights, Emerald Village, Worthdale and Biltmore Hills. Coastal Credit Union Music Park (formerly Time Warner Cable Music Pavilion, Alltel Pavilion and Walnut Creek Amphitheatre) is one of the region's major outdoor concert venues and is located on Rock Quarry Road. Shaw University is located in this part of the city. Starting in 2020, large tracts of formerly unoccupied land along Rock Quarry Road between New Hope Road and Barwell Road, and between Barwell Road and Battle Bridge Road, have been cleared for new developments.
=== Research === Hepatitis B and its related disorders are important public health issues in China, which not only presents challenges for doctors and scientists but also increases the burden for the government. Last year, the Chinese Government funded research with around Ɲ3 billion (US$390 million), mainly against hepatitis B and related diseases over the next decade. Research will include: large retrospective and prospective studies of the population vaccinated against hepatitis B and the incidence of HCC; genetic variation in HBV and its subtypes, and mutations in HBV DNA in the response to interferon and nucleotide analogues; host-gene variation and the therapeutic response, including single-nuclear polymorphisms and gene copy-number variations; virus mutation and the mechanism of the immune response in fulminant liver failure, and the immunological factors which cause liver injury and the markers which predict reduction in liver function; assessment and prediction of liver fibrosis by non-invasive biomarkers, and interference with fibrosis from small chemical compounds or traditional Chinese medicines; prediction of the development, metastasis, and prognosis of HCC by molecular typing; and the identification of important signal transduction pathways in HCC and the development of new small chemical compounds to target HCC.
== Veterinary use == Fentanyl is commonly used for analgesia and as a component of balanced sedation and general anesthesia in small animal patients. The short-acting nature, wide safety profile, lower rate of adverse effect compared to other opioids, and high potency make fentanyl one of the most effective and common analgesics in veterinary medicine; the ability to reduce the minimum alveolar concentration leads to fentanyl being commonly used in dogs that are elderly or have cardiovascular issues. Due to its short duration and quick onset, fentanyl is commonly used as a constant rate infusion or as a transdermal patch, with the latter being able to last 3 to 4 days. Fentanyl can provide sedation for dogs. Fentanyl is less common and has more adverse effects in livestock and equine compared to cats and dogs. In horses at analgesic doses tachycardia, restlessness, and excitement occur. Subcutaneous administration often causes pain, but a bicarbonate solution exists which does not cause pain when given subcutaneously. Fentanyl is highly lipophilic, about 1000 times more than morphine. In dogs it has low protein binding of 15.6% and a half-life of 2–6 hours. In cats the half-life is 2.5 hours. Fentanyl has poor oral bio-availability due to it being metabolized by the liver. Transdermal and transmucosal formulations are common for out-patients, although the latter's efficacy is not well supported by evidence.
Sources: en.wikipedia.org
In 2019, the FDA issued a drug safety warning about serious breathing difficulties in patients using pregabalin or gabapentin, particularly when combined with opioids or other CNS depressants. A 2022 meta-analysis found that combination therapy with opioids and gabapentinoids could be associated with an increased risk of CNS depression and mortality, and concluded that combination therapy with these medications requires close clinical monitoring. Combined use of pregabalin and alcohol produces additive impairment of cognitive and psychomotor function, as both substances act as central nervous system depressants. The pregabalin prescribing information advises against alcohol consumption during treatment, noting that the CNS depressant effects of the two substances compound one another. The combination of pregabalin and benzodiazepines produces additive CNS and respiratory depression, with pregabalin pharmacodynamically augmenting benzodiazepine sedation. A 2020 study published in the British Journal of Anaesthesia examining gabapentinoid prescribing trends in Scotland found that among recurrent gabapentinoid users, benzodiazepines were co-prescribed in 26.8% of cases, opioids in 49.9%, and both in a further 17.1%, and that the age-standardised death rate among those prescribed gabapentinoids was double that of the general Scottish population. The prescribing information for pregabalin advises monitoring for respiratory depression and sedation when co-prescribing with benzodiazepines.
Lisdexamphetamine was developed by Robert Oberlender at New River Pharmaceuticals, under the name NRP104, before being bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, prior to market release. It was developed to create a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration. In February 2007, the US Food and Drug Administration (FDA) approved lisdexamphetamine for the treatment of ADHD. In August 2009, Health Canada approved the marketing of lisdexamphetamine for prescription use. In January 2015, lisdexamphetamine was approved by the FDA for the treatment of binge eating disorder in adults. The FDA gave tentative approval to generic formulations of lisdexamphetamine in 2015. The expiration date for patent protection of lisdexamphetamine in the US was 24 February 2023. The Canadian patent expired 20 years from the filing date of 1 June 2004. Production quotas for 2016 in the United States were 29,750 kg.
In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat neuroses. While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects. Today, "minor tranquilizer" can refer to anxiolytic and/or hypnotic drugs such as the benzodiazepines and nonbenzodiazepines, which are useful as generally short-term management for insomnia together with cognitive behavioral therapy for insomnia. They are potentially addictive sedatives. Antipsychotics are broadly divided into two groups, the typical or first-generation antipsychotics and the atypical or second-generation antipsychotics. The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of 5HT2A receptor antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics.
== Reactivity == Thiotepa is a reactive compound that, under acidic, neutral, or alkaline conditions, undergoes solvolysis, leading to potential side reactions such as polymerization and dimerization into piperazines. During acidic degradation, thiotepa reacts with chloride ions to produce monochloro, dichloro, and trichloro derivatives. Acidic conditions also result in the formation of tepa (N,N′,N″-triethylenephosphoramide), the first identified and more reactive metabolite of thiotepa. In alkaline media, thiotepa undergoes degradation, though no detectable byproducts were identified. Like other aziridine-containing compounds, hydroxyl substitution reactions may release aziridine. This degradation pathway has also been reported for tepa. The stability of thiotepa in biological samples is dependent on pH. In plasma, the monochloro derivative of thiotepa is formed, while in urine, both monochloro and dichloro derivatives have been found. Thiotepa is most stable between pH 7 and 11. In plasma under physiological conditions, the compound has a half-life of five days, whereas in urine at 37 °C, the half-life is 16 minutes at pH 4 and 21 hours at pH 6.
In December 2025, the US began blockading Venezuelan waters and directly targeting Venezuelan oil tankers. Special forces launched from USS Gerald R. Ford seized a tanker off the coast of Venezuela on 10 December 2025. The US planned additional seizures of vessels transporting Venezuelan crude, imposed additional sanctions on Maduro's family and Venezuelan oil shipments, Trump demanded the return of nationalized oil and land resources he said were seized from US corporations by the Chávez government in 2007, and announced the US would designate the "Maduro regime" a Foreign Terrorist Organization.
Sources: en.wikipedia.org
== Interaction with Antibiotics == The ribosomal tunnel contains binding sites for clinically important antibiotics, such as macrolides or streptogramins. Antibiotics bind to the inner part of the ribosomal tunnel, either near the peptidyl transferase center or near the constriction site. Despite the original belief that macrolide binding to the tunnel causes obstruction, it has been shown that the tunnel remains permeable. Antibiotics instead stabilize the catalytic site of the ribosome in a conformation that is unproductive for peptide bond formation, causing translational arrest. Translational arrest of the ribosome may also be dependent on the sequence of the nascent peptide, as has been observed, for example with chloramphenicol.
=== Effects during pregnancy === During human pregnancy, increased fetal production of cortisol between weeks 30 and 32 initiates production of fetal lung pulmonary surfactant to promote maturation of the lungs. In fetal lambs, glucocorticoids (principally cortisol) increase after about day 130, with lung surfactant increasing greatly, in response, by about day 135, and although lamb fetal cortisol is mostly of maternal origin during the first 122 days, 88% or more is of fetal origin by day 136 of gestation. Although the timing of fetal cortisol concentration elevation in sheep may vary somewhat, it averages about 11.8 days before the onset of labor. In several livestock species (e.g. cattle, sheep, goats, and pigs), the surge of fetal cortisol late in gestation triggers the onset of parturition by removing the progesterone block of cervical dilation and myometrial contraction. The mechanisms yielding this effect on progesterone differ among species. In the sheep, where progesterone sufficient for maintaining pregnancy is produced by the placenta after about day 70 of gestation, the prepartum fetal cortisol surge induces placental enzymatic conversion of progesterone to estrogen. (The elevated level of estrogen stimulates prostaglandin secretion and oxytocin receptor development.) Exposure of fetuses to cortisol during gestation can have a variety of developmental outcomes, including alterations in prenatal and postnatal growth patterns.
They can sedate patients receiving mechanical ventilation or those in extreme distress. Caution is exercised in this situation due to the risk of respiratory depression, and it is recommended that benzodiazepine overdose treatment facilities should be available. They have also been found to increase the likelihood of later PTSD after people have been removed from ventilators. Benzodiazepines are indicated in the management of breathlessness (shortness of breath) in advanced diseases, in particular where other treatments have failed to adequately control symptoms. Benzodiazepines are effective as medication given a couple of hours before surgery to relieve anxiety. They also produce amnesia, which can be useful, as patients may not remember unpleasantness from the procedure. They are also used in patients with dental phobia as well as some ophthalmic procedures like refractive surgery; although such use is controversial and only recommended for those who are very anxious. Midazolam is the most commonly prescribed for this use because of its strong sedative actions and fast recovery time, as well as its water solubility, which reduces pain upon injection. Diazepam and lorazepam are sometimes used. Lorazepam has particularly marked amnesic properties that may make it more effective when amnesia is the desired effect. Benzodiazepines are well known for their strong muscle-relaxing properties and can be useful in the treatment of muscle spasms, although tolerance often develops to their muscle-relaxant effects.
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. Imetelstat is an oligonucleotide telomerase inhibitor. By blocking telomerase activity, imetelstat causes telomere shortening, inhibits the proliferation of malignant stem and progenitor cells and induces cell death, ultimately leading to a reduction in malignant clones. The most common adverse reactions include decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache. Imetelstat was approved for medical use in the United States in June 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
The genetic code (the "translation table" according to which DNA information is translated into amino acids, and hence proteins) is nearly identical for all known lifeforms, from bacteria and archaea to animals and plants. The universality of this code is generally regarded by biologists as definitive evidence in favor of universal common descent. The way that codons (DNA triplets) are mapped to amino acids seems to be strongly optimised. Richard Egel argues that in particular the hydrophobic (non-polar) side-chains are well organised, suggesting that these enabled the earliest organisms to create peptides with water-repelling regions able to support the essential electron exchange (redox) reactions for energy transfer.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.